Citadel Advisors - NEUBASE THERAPEUTICS INC ownership

NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 48 filers reported holding NEUBASE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of NEUBASE THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$9,000
-70.0%
22,799
+41.6%
0.00%
Q1 2022$30,000
-63.9%
16,100
-45.5%
0.00%
Q4 2021$83,000
+27.7%
29,528
+64.0%
0.00%
Q3 2021$65,000
-80.4%
18,000
-73.9%
0.00%
Q2 2021$332,000
+88.6%
69,077
+190.0%
0.00%
Q1 2021$176,000
-39.9%
23,818
-43.1%
0.00%
Q4 2020$293,000
+44.3%
41,849
+56.6%
0.00%
Q3 2020$203,000
-21.9%
26,730
-9.8%
0.00%
Q2 2020$260,000
+205.9%
29,618
+150.6%
0.00%
Q4 2019$85,00011,8210.00%
Other shareholders
NEUBASE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Greenlight Capital 2,027,027$14,169,0000.85%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 103,500$723,0000.55%
Sio Capital Management, LLC 293,699$2,053,0000.42%
GSA CAPITAL PARTNERS LLP 121,389$849,0000.14%
Frontier Wealth Management LLC 145,000$1,014,0000.08%
PRELUDE CAPITAL MANAGEMENT, LLC 311,000$2,174,0000.06%
Oak Grove Capital LLC 19,175$134,0000.04%
PREMIER ASSET MANAGEMENT LLC 14,977$105,0000.02%
Trexquant Investment LP 15,479$108,0000.01%
PILLAR PACIFIC CAPITAL MANAGEMENT LLC 19,800$138,0000.01%
View complete list of NEUBASE THERAPEUTICS INC shareholders